EV sales in Australia surge despite market downturn
The Australian automotive landscape witnessed a historic pivot in March as electric vehicle sales surged to record heights
The Australian automotive landscape witnessed a historic pivot in March as electric vehicle sales surged to record heights
West Australian gold miner Ramelius Resources (ASX:RMS) has reaffirmed its production targets for the 2025–26 financial year.
Australian data centre giant NEXTDC (ASX:NXT) announced a $1 billion wholesale offer of subordinated hybrid securities.
Amplia Therapeutics (ASX:ATX) announced a shift in its clinical programme, halting further recruitment for the AMPLICITY trial.
GoPro (NASDAQ:GPRO) announced on April 7, 2026, that its Board of Directors has approved a comprehensive restructuring plan designed to significantly reduce operating costs and accelerate the company’s push toward stronger operating leverage.
Skillsoft (NYSE:SKIL), a global leader in corporate digital learning and skills management, reported its financial results for the fourth quarter and full fiscal year ended January 31, 2026, on April 7, 2026.
SolarMax Technology (NASDAQ:SMXT), a leading integrated solar energy company, announced record financial results for the fiscal year ended December 31, 2025, marked by a near-fourfold increase in revenue and a significant expansion of its energy storage pipeline.
Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.
TransDigm Group (NYSE:TDG), a leading global designer, producer, and supplier of highly engineered aircraft components, announced on April 7, 2026, the successful completion of its acquisition of Jet Parts Engineering and Victor Sierra Aviation Holdings for approximately $2.2 billion in cash.
Savara (NASDAQ:SVRA), a clinical-stage biopharmaceutical company dedicated to rare respiratory diseases, announced on April 7, 2026, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
